STVN
Get informed when a big investor buys or sells
+ FollowOvervalued by 78.1% based on the discounted cash flow analysis.
| Market cap | $4.87 Billion |
|---|---|
| Enterprise Value | $5.30 Billion |
| Dividend Yield | $0.06 (0.35%) |
| Earnings per Share | $0.49 |
| Beta | 0.78 |
| Outstanding Shares | 273,003,694 |
| P/E Ratio | 30.71 |
|---|---|
| PEG | 538.54 |
| Price to Sales | 4.46 |
| Price to Book Ratio | 3.57 |
| Enterprise Value to Revenue | 4.41 |
| Enterprise Value to EBIT | 26.5 |
| Enterprise Value to Net Income | 37 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.35 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 24,000▲ Infinity% |
Holdings and activity of institutional investors.
| Ownership % | 16.32%▼ 2.12% |
|---|---|
| Total Invested | $612.72M▼ 40.54% |
| Investors Holding | 136▼ 3.00% |
No data
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end por...